BRPI0717218A2 - inibidor da ativaÇço, e, mÉtodo para previnir ou tratat um sintoma ou doenÇa. - Google Patents
inibidor da ativaÇço, e, mÉtodo para previnir ou tratat um sintoma ou doenÇa.Info
- Publication number
- BRPI0717218A2 BRPI0717218A2 BRPI0717218-4A2A BRPI0717218A BRPI0717218A2 BR PI0717218 A2 BRPI0717218 A2 BR PI0717218A2 BR PI0717218 A BRPI0717218 A BR PI0717218A BR PI0717218 A2 BRPI0717218 A2 BR PI0717218A2
- Authority
- BR
- Brazil
- Prior art keywords
- symptom
- disease
- treating
- preventing
- activation inhibitor
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006271172 | 2006-10-02 | ||
| PCT/JP2007/069645 WO2008044667A1 (en) | 2006-10-02 | 2007-10-02 | Stat3/5 activation inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0717218A2 true BRPI0717218A2 (pt) | 2013-09-24 |
Family
ID=38896700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717218-4A2A BRPI0717218A2 (pt) | 2006-10-02 | 2007-10-02 | inibidor da ativaÇço, e, mÉtodo para previnir ou tratat um sintoma ou doenÇa. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8263599B2 (pt) |
| EP (2) | EP2612858A1 (pt) |
| JP (1) | JP5068821B2 (pt) |
| KR (1) | KR101148805B1 (pt) |
| CN (1) | CN101522657B (pt) |
| AR (1) | AR063073A1 (pt) |
| AU (1) | AU2007305511A1 (pt) |
| BR (1) | BRPI0717218A2 (pt) |
| CA (1) | CA2665000C (pt) |
| IL (1) | IL197723A (pt) |
| MX (1) | MX2009003256A (pt) |
| MY (1) | MY150229A (pt) |
| NO (1) | NO20090856L (pt) |
| NZ (1) | NZ598061A (pt) |
| RU (1) | RU2489148C2 (pt) |
| TW (1) | TWI336699B (pt) |
| UA (1) | UA95978C2 (pt) |
| WO (1) | WO2008044667A1 (pt) |
| ZA (1) | ZA200901874B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| PL1940786T3 (pl) | 2005-09-16 | 2010-12-31 | Arrow Therapeutics Ltd | Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C |
| EP1957073B1 (en) * | 2005-12-05 | 2014-04-23 | Otsuka Pharmaceutical Co., Ltd. | Medicinal drug |
| NZ590355A (en) | 2008-07-10 | 2013-01-25 | Yakult Honsha Kk | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| JP5688918B2 (ja) * | 2009-04-28 | 2015-03-25 | 大塚製薬株式会社 | 医薬組成物 |
| JP5794922B2 (ja) * | 2009-12-28 | 2015-10-14 | 一般社団法人ファルマバレープロジェクト支援機構 | １，３，４−オキサジアゾール−２−カルボキサミド化合物 |
| PH12012501532A1 (en) | 2010-01-29 | 2012-10-22 | Otsuka Pharma Co Ltd | Di-substituted pyridine derivatives as anticancers |
| NZ609151A (en) * | 2010-10-04 | 2015-01-30 | Otsuka Pharma Co Ltd | 4-(methylaminophenoxy)pyridin-3-yl-benzamide derivatives for treating cancer |
| CN102921007B (zh) * | 2011-08-09 | 2014-12-10 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
| TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
| JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
| HK1218709A1 (zh) * | 2012-05-25 | 2017-03-10 | 多伦多大学管理委员会 | 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 |
| CN103880707B (zh) * | 2012-12-19 | 2016-04-13 | 上海交通大学医学院 | Stat3小分子抑制剂及其应用 |
| WO2015006100A1 (en) * | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| NZ726874A (en) * | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
| WO2015179956A1 (en) | 2014-05-30 | 2015-12-03 | The Governing Council Of The University Of Toronto | Sulfonamide compounds and their use as stat5 inhibitors |
| KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| CN110573151A (zh) | 2017-04-26 | 2019-12-13 | 辛辛那提大学 | 用于治疗急性髓性白血病的方法、试剂和组合物 |
| TWI650120B (zh) * | 2017-07-21 | 2019-02-11 | 寶騰生醫股份有限公司 | 一種醫藥組成物用於製備治療或預防個體感染病毒之藥物的用途 |
| US10882821B1 (en) | 2017-09-26 | 2021-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
| CN111763217B (zh) * | 2019-03-30 | 2022-06-28 | 上海凌达生物医药有限公司 | 一类噻吩并氮杂环类化合物、制备方法和用途 |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| RU2742188C1 (ru) * | 2020-07-22 | 2021-02-03 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. | Способ лечения оптической нейропатии у больных с отечным экзофтальмом |
| CN116715657B (zh) * | 2023-04-19 | 2025-07-11 | 河南省锐达医药科技有限公司 | 一种二芳基乙炔类化合物、其制备方法及应用 |
| CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE629102A (pt) | 1961-03-29 | |||
| NL7111711A (pt) | 1970-09-17 | 1972-03-21 | ||
| US3715375A (en) | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
| GB1494117A (en) | 1974-11-02 | 1977-12-07 | Bayer Ag | Process for the preparation of acid amides |
| DE2707660C2 (de) | 1977-02-23 | 1985-12-19 | Bayer Ag, 5090 Leverkusen | Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung |
| DE2707659A1 (de) | 1977-02-23 | 1978-08-24 | Bayer Ag | Selbstvernetzbare polyurethane |
| DE2812252A1 (de) | 1978-03-21 | 1979-10-04 | Bayer Ag | 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| EP0500495A3 (en) | 1991-02-21 | 1993-04-07 | Ciba-Geigy Ag | Thermosetting composition |
| EP0580550B1 (en) | 1992-07-21 | 1997-10-22 | Novartis AG | Oxamic acid derivatives as hypocholesteremic agents |
| JP3894949B2 (ja) | 1993-06-30 | 2007-03-22 | ザ、ウェルカム、ファンデーション、リミテッド | 抗アテローム性動脈硬化症ジアリール化合物 |
| AU702423B2 (en) | 1995-06-07 | 1999-02-18 | Institute Of Materia Medica | Chalcone retinoids and methods of use of same |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| ES2233025T3 (es) | 1998-02-06 | 2005-06-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Agente inhibidores de la triptasa. |
| EP1060171A2 (de) | 1998-02-06 | 2000-12-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase-inhibitoren |
| AR015733A1 (es) | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
| TWI245035B (en) | 1998-06-26 | 2005-12-11 | Ono Pharmaceutical Co | Amino acid derivatives and a pharmaceutical composition comprising the derivatives |
| KR100682276B1 (ko) | 1998-07-24 | 2007-02-28 | 데이진 가부시키가이샤 | 안트라닐산 유도체 |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1150955A2 (en) | 1999-02-04 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
| CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
| US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
| EP1193255A4 (en) | 1999-07-01 | 2002-08-07 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE |
| JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| JP2001089450A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
| AU2001234089B2 (en) | 2000-02-15 | 2005-08-11 | Teijin Limited | Cancer remedy comprising anthranilic acid derivative as active ingredient |
| DZ3347A1 (fr) | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| IL155097A0 (en) | 2000-09-28 | 2003-10-31 | Nanocyte Inc | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| AU2002223626A1 (en) | 2000-10-20 | 2002-04-29 | Novartis Ag | Combinations of a thyromimetic compound and a statin |
| EP1211235A3 (en) | 2000-11-30 | 2004-01-02 | JFE Chemical Corporation | Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof |
| JP2004269356A (ja) | 2000-12-27 | 2004-09-30 | Ajinomoto Co Inc | 創傷部癒着防止剤 |
| GB2374009A (en) | 2001-02-12 | 2002-10-09 | Novartis Ag | Method of treating hair loss |
| HUP0400369A2 (hu) | 2001-06-20 | 2004-12-28 | Pfizer Products Inc. | Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| MXPA04000779A (es) | 2001-08-24 | 2004-04-20 | Pharmacia & Up John Company | 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades. |
| EP1438298B1 (en) | 2001-10-22 | 2010-01-27 | Pfizer Products Inc. | Piperazine derivatives with ccr1 receptor antagonist activity |
| WO2003035602A1 (en) | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Lipid modulators |
| US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| FR2836917B1 (fr) * | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| JP2004035475A (ja) | 2002-07-03 | 2004-02-05 | Ajinomoto Co Inc | ＴＧＦβ作用抑制剤 |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| RU2396250C2 (ru) | 2003-07-24 | 2010-08-10 | Лео Фарма А/С | Новые производные аминобензофенона |
| US8188277B2 (en) * | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| EP1957073B1 (en) * | 2005-12-05 | 2014-04-23 | Otsuka Pharmaceutical Co., Ltd. | Medicinal drug |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2007
- 2007-02-10 UA UAA200904059A patent/UA95978C2/ru unknown
- 2007-10-01 AR ARP070104333A patent/AR063073A1/es unknown
- 2007-10-02 WO PCT/JP2007/069645 patent/WO2008044667A1/en not_active Ceased
- 2007-10-02 EP EP13153028.9A patent/EP2612858A1/en not_active Withdrawn
- 2007-10-02 US US12/311,500 patent/US8263599B2/en not_active Expired - Fee Related
- 2007-10-02 BR BRPI0717218-4A2A patent/BRPI0717218A2/pt not_active IP Right Cessation
- 2007-10-02 CN CN200780036608.8A patent/CN101522657B/zh not_active Expired - Fee Related
- 2007-10-02 EP EP07829383A patent/EP2089373A1/en not_active Withdrawn
- 2007-10-02 AU AU2007305511A patent/AU2007305511A1/en not_active Abandoned
- 2007-10-02 ZA ZA200901874A patent/ZA200901874B/xx unknown
- 2007-10-02 RU RU2009116653/15A patent/RU2489148C2/ru not_active IP Right Cessation
- 2007-10-02 CA CA2665000A patent/CA2665000C/en not_active Expired - Fee Related
- 2007-10-02 NZ NZ598061A patent/NZ598061A/xx not_active IP Right Cessation
- 2007-10-02 MY MYPI20091324A patent/MY150229A/en unknown
- 2007-10-02 KR KR1020097006358A patent/KR101148805B1/ko not_active Expired - Fee Related
- 2007-10-02 JP JP2009529959A patent/JP5068821B2/ja not_active Expired - Fee Related
- 2007-10-02 TW TW096136957A patent/TWI336699B/zh not_active IP Right Cessation
- 2007-10-02 MX MX2009003256A patent/MX2009003256A/es active IP Right Grant
-
2009
- 2009-02-25 NO NO20090856A patent/NO20090856L/no not_active Application Discontinuation
- 2009-03-19 IL IL197723A patent/IL197723A/en not_active IP Right Cessation
-
2012
- 2012-06-18 US US13/526,283 patent/US20120322807A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090043008A (ko) | 2009-05-04 |
| AU2007305511A1 (en) | 2008-04-17 |
| IL197723A (en) | 2015-02-26 |
| RU2489148C2 (ru) | 2013-08-10 |
| AR063073A1 (es) | 2008-12-23 |
| US20120322807A1 (en) | 2012-12-20 |
| NO20090856L (no) | 2009-03-27 |
| CA2665000A1 (en) | 2008-04-17 |
| EP2612858A1 (en) | 2013-07-10 |
| UA95978C2 (ru) | 2011-09-26 |
| HK1131619A1 (en) | 2010-01-29 |
| WO2008044667A1 (en) | 2008-04-17 |
| ZA200901874B (en) | 2010-07-28 |
| EP2089373A1 (en) | 2009-08-19 |
| JP5068821B2 (ja) | 2012-11-07 |
| RU2009116653A (ru) | 2010-11-10 |
| CN101522657B (zh) | 2014-10-15 |
| CN101522657A (zh) | 2009-09-02 |
| US20100210661A1 (en) | 2010-08-19 |
| CA2665000C (en) | 2015-03-24 |
| MX2009003256A (es) | 2009-04-08 |
| JP2010505762A (ja) | 2010-02-25 |
| TW200823189A (en) | 2008-06-01 |
| KR101148805B1 (ko) | 2012-07-10 |
| US8263599B2 (en) | 2012-09-11 |
| IL197723A0 (en) | 2009-12-24 |
| TWI336699B (en) | 2011-02-01 |
| MY150229A (en) | 2013-12-31 |
| NZ598061A (en) | 2013-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0717480A2 (pt) | Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto. | |
| BRPI0619586A2 (pt) | método para o tratamento ou prevenção de um distúrbio associado com cd40 | |
| BRPI0815708A2 (pt) | Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição. | |
| BRPI0815707A2 (pt) | Processo para a liquefação de uma corrente gasosa, e, sistema para o tratamento de uma corrente de alimentação gasosa. | |
| BRPI0915773A2 (pt) | stent, válvula, e, método para tratar um paciente | |
| BRPI0716172A2 (pt) | instalaÇço de remoÇço de revestimento e mÉtodo para operaÇço da mesma. | |
| BRPI0717753A2 (pt) | Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição. | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| BRPI0717637A2 (pt) | Mecanismo de válvula de cunha giratória, e, método para fabricar um membro de válvula de cunha giratória | |
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| BRPI0820830A2 (pt) | Método para modelar em um computador para região física, e, produto de programa de computador. | |
| BRPI0810356A2 (pt) | Sistema de aquecimento para uma formação de subsuperfície, e, método para aquecer uma formação de subsuperfície. | |
| BRPI0815681A2 (pt) | Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção. | |
| BRPI0920253A2 (pt) | dispositivo de agulha cirúrgica, sistema de agulha cirúrgica, e, método para usar um dispositivo de agulha cirúrgica. | |
| BRPI0916576A2 (pt) | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BRPI0816442A2 (pt) | dispensador de produto, e, método para operar o mesmo | |
| BRPI0816443A2 (pt) | dispensador de produto, e, método para operar o mesmo | |
| BRPI0816859A2 (pt) | Artigo para fumar, e, método para fabricar um artigo para fumar. | |
| BRPI0815318A2 (pt) | "método e sistema para avaliação de uma condição de um componente". | |
| BRPI0717757A2 (pt) | Derivado de haloalquilsulfoanilida ou um sal do mesmo, herbicida, e, método para usar um herbicida | |
| BRPI0812508A2 (pt) | Dispositivo e processo para controlar um dispositivo de freio. | |
| DE602007006610D1 (de) | Isolationsdurchdringendes und SMD fähiges Kontaktelement , sowie Verfahren zu dessen Nutzung. | |
| BRPI0922066A2 (pt) | processos para a fabricação de metilmercaptopropionaldeido e da metionina ou do hidroxianalogo da metionina, metilmercaptopropinaldeido,metionina ou hidroxianalogo da metionina, e, utilização da metionina ou do hidroxianalogo da metionina. | |
| BRPI0718974A2 (pt) | Copolímero, e, método para preparar um copolímero |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |